[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100098668":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":36,"centralContacts":11,"locations":40,"responsibleParty":11,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Heidelberg University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"1-Methylenblue-Amodiaquine","ACTIVE_COMPARATOR",null,[13],"Drug: Methylenblue-Amodiaquine (MB-AQ)",{"label":15,"type":10,"description":11,"interventionNames":16},"2-Methylenblue-Artesunate",[17],"Drug: Methylenblue-Artesunate (MB-AS)",{"label":19,"type":10,"description":11,"interventionNames":20},"3-Artesunate-Amodiaquine",[21],"Drug: Artesunate-Amodiaquine (AS-AQ)",[23,28,32],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","Methylenblue-Amodiaquine (MB-AQ)","For 3 days twice daily 10 mg\u002Fkg MB accompanied by once daily 10 mg\u002Fkg AQ",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"Methylenblue-Artesunate (MB-AS)","3 days once daily 4 mg\u002Fkg AS accompanied by twice daily 10 mg\u002Fkg MB given over 7 days",[15],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"Artesunate-Amodiaquine (AS-AQ)","For 3 days once daily 10 mg\u002Fkg AQ accompanied by 4mg\u002Fkg AS.",[19],[37],{"name":38,"affiliation":5,"role":39},"Olaf Mueller, Prof.","PRINCIPAL_INVESTIGATOR",[41],{"facility":42,"status":11,"city":43,"state":11,"zip":11,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":11},"Centre de Recherche en Sante de Nouna","Nouna","Burkina Faso","BF",{"type":47,"coordinates":48},"Point",[49,50],-3.86305,12.72939,{"lat":50,"lon":49},"100098668","phase-2-safety-and-efficacy-of-methylene-blue-combined-with-amodiaquine-or-artesunate-for-malaria-treatment-in-children-of-burkina-faso-100098668",false,"NCT00545935","Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso","Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso: RCT in the Frame of the A8 Project of SFB 544","Inclusion Criteria:\n\n* 0.5-5 year (6-59 months) old children\n* uncomplicated malaria caused by P. falciparum\n* asexual parasites ≥ 2000\u002Fµ and ≤ 200000\u002Fµ\n* axillary temperature ≥ 37.5 Celsius or a history of fever during last 24 hours\n* Burkinabe nationality\n* informed consent\n\nExclusion Criteria:\n\n* complicated or severe malaria\n* any apparent significant disease\n* anaemia (haematocrit \\\u003C 21%)\n* treated in the same trial before\n* modern antimalarial treatment prior to inclusion (last three days), except children having been treated with chloroquine","ALL","6 Months","59 Months",{"count":63,"type":11},186,"INTERVENTIONAL",[66],"PHASE2","The purpose of the study is to investigate the safety and efficacy profile of a new paediatric MB formulation combined with AQ or AS and compared to AS-AQ in young African children with uncomplicated falciparum malaria.",[69],"Malaria","COMPLETED","2009-02-02",{"date":73,"type":74},"2009-02-03","ESTIMATED",{"date":76,"type":11},"2007-07",{"date":78,"type":11},"2007-10",{"name":5,"class":6},1]